|
1
|
Mezzanzanica D: Ovarian cancer: A
molecularly insidious disease. Chin J Cancer. 34:1–3. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Galluzzi L, Senovilla L, Vitale I, Michels
J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms
of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rancoule C, Guy JB, Vallard A, Ben Mrad M,
Rehailia A and Magné N: 50th anniversary of cisplatin. Bull Cancer.
104:167–176. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Armstrong DK, Bundy B, Wenzel L, Huang HQ,
Baergen R, Lele S, Copeland LJ, Walker JL and Burger RA;
Gynecologic Oncology Group, : Intraperitoneal cisplatin and
paclitaxel in ovarian cancer. N Engl J Med. 354:34–43. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tomao F, Marchetti C, Romito A, Di Pinto
A, Di Donato V, Capri O, Palaia I, Monti M, Muzii L and Benedetti
Panici P: Overcoming platinum resistance in ovarian cancer
treatment: From clinical practice to emerging chemical therapies.
Expert Opin Pharmacother. 18:1443–1455. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jarroux J, Morillon A and Pinskaya M:
History, discovery, and classification of lncRNAs. Adv Exp Med
Biol. 1008:1–46. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wieczorek E and Reszka E: mRNA, microRNA
and lncRNA as novel bladder tumor markers. Clin Chim Acta.
477:141–153. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Marchese FP, Raimondi I and Huarte M: The
multidimensional mechanisms of long noncoding RNA function. Genome
Biol. 18:2062017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hu B, Zhang H, Wang Z, Zhang F, Wei H and
Li L: LncRNA CCAT1/miR-130a-3p axis increases cisplatin resistance
in non-small-cell lung cancer cell line by targeting SOX4. Cancer
Biol Ther. 18:974–983. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu Y and Wang H: LncRNA NEAT1 promotes
dexamethasone resistance in multiple myeloma by targeting
miR-193a/MCL1 pathway. J Biochem Mol Toxicol. 32:e220082018.
View Article : Google Scholar
|
|
12
|
Chen P, Fang X, Xia B, Zhao Y, Li Q and Wu
X: Long noncoding RNA LINC00152 promotes cell proliferation through
competitively binding endogenous miR-125b with MCL-1 by regulating
mitochondrial apoptosis pathways in ovarian cancer. Cancer Med.
7:4530–4541. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ma J, Yang J, Wang C, Zhang N, Dong Y,
Wang C, Wang Y and Lin X: Emodin augments cisplatin cytotoxicity in
platinum-resistant ovarian cancer cells via ROS-dependent MRP1
downregulation. Biomed Res Int. 2014:1076712014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang T, Guan M, Jin HY and Lu Y: Reversal
of multidrug resistance by small interfering double-stranded RNAs
in ovarian cancer cells. Gynecol Oncol. 97:501–507. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang F, Zhu Y, Fang S, Li S and Liu S:
Effect of lanthanum chloride on tumor growth and apoptosis in human
ovarian cancer cells and xenograft animal models. Exp Ther Med.
16:1143–1148. 2018.PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pogge von Strandmann E, Reinartz S, Wager
U and Müller R: Tumor-Host cell interactions in ovarian cancer:
Pathways to therapy failure. Trends Cancer. 3:137–148. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kujawa KA and Lisowska KM: Ovarian
cancer-from biology to clinic. Postepy Hig Med Dosw (Online).
69:1275–1290. 2015.(In Polish). View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mitra R, Chen X, Greenawalt EJ, Maulik U,
Jiang W, Zhao Z and Eischen CM: Decoding critical long non-coding
RNA in ovarian cancer epithelial-to-mesenchymal transition. Nat
Commun. 8:16042017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Worku T, Bhattarai D, Ayers D, Wang K,
Wang C, Rehman ZU, Talpur HS and Yang L: Long non-coding RNAs: The
new horizon of gene regulation in ovarian cancer. Cell Physiol
Biochem. 44:948–966. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Martini P, Paracchini L, Caratti G,
Mello-Grand M, Fruscio R, Beltrame L, Calura E, Sales G, Ravaggi A,
Bignotti E, et al: lncRNAs as novel indicators of patients'
prognosis in stage I epithelial ovarian cancer: A retrospective and
multicentric study. Clin Cancer Res. 23:2356–2366. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu J, Wu J, Fu C, Teng F, Liu S, Dai C,
Shen R and Jia X: Multidrug resistant lncRNA profile in
chemotherapeutic sensitive and resistant ovarian cancer cells. J
Cell Physiol. 233:5034–5043. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu QF, Tang YX and Wang X: LncRNA EBIC
promoted proliferation, metastasis and cisplatin resistance of
ovarian cancer cells and predicted poor survival in ovarian cancer
patients. Eur Rev Med Pharmacol Sci. 22:4440–4447. 2018.PubMed/NCBI
|
|
24
|
Wang Y, Wang H, Song T, Zou Y, Jiang J,
Fang L and Li P: HOTAIR is a potential target for the treatment of
cisplatin-resistant ovarian cancer. Mol Med Rep. 12:2211–2216.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang C, Wang M, Shi C, Shi F and Pei C:
Long non-coding RNA Linc00312 modulates the sensitivity of ovarian
cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway.
Biosci Trends. 12:309–316. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yue B, Cai D, Liu C, Fang C and Yan D:
Linc00152 Functions as a competing endogenous RNA to confer
oxaliplatin resistance and holds prognostic values in colon cancer.
Mol Ther. 24:2064–2077. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guo F, Cao Z, Guo H and Li S: The action
mechanism of lncRNA-HOTAIR on the drug resistance of non-small cell
lung cancer by regulating Wnt signaling pathway. Exp Ther Med.
15:4885–4889. 2018.PubMed/NCBI
|
|
28
|
Li H, Yuan X, Yan D, Li D, Guan F, Dong Y,
Wang H, Liu X and Yang B: Long non-coding RNA MALAT1 decreases the
sensitivity of resistant glioblastoma cell lines to temozolomide.
Cell Physiol Biochem. 42:1192–1201. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhu J, Zhang R, Yang D, Li J, Yan X, Jin
K, Li W, Liu X, Zhao J, Shang W and Yu T: Knockdown of long
non-coding RNA XIST inhibited doxorubicin resistance in colorectal
cancer by upregulation of miR-124 and downregulation of SGK1. Cell
Physiol Biochem. 51:113–128. 2018. View Article : Google Scholar : PubMed/NCBI
|
